02.06.2013 Views

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

206 EPIRUBICIN<br />

Other<br />

Anaphylactoid reactions/Anaphylaxis<br />

Hot flashes (5–39%)<br />

Hypersensitivity<br />

Injection-site extravasation<br />

(1999): Fleming A+, JH<strong>and</strong>Surg[Br]24, 390<br />

Injection-site inflammation<br />

Injection-site necrosis<br />

Injection-site reactions (sic) (3–20%)<br />

Injection-site ulceration<br />

Myalgia/Myositis/Myopathy/Myotoxicity (55%)<br />

(1995): Fountzilas G+, Med Pediatr Oncol 24, 23 (55%)<br />

Phlebitis<br />

Sjogren’s (Sicca) syndrome<br />

(1986): Oxholm A+, Lancet 2(8507), 629<br />

EPLERENONE<br />

Trade name: Inspra (Pfizer)<br />

Indications: Hypertension<br />

Category: Aldosterone antagonist; Diuretic<br />

Half-life: 4–6 hours<br />

Clinically important, potentially hazardous interactions<br />

with: ACE inhibitors, angiotensin ii receptor antagonists,<br />

erythromycin, fluconazole, grapefruit juice, itraconazole,<br />

ketoconazole, saquinavir, St John’s wort, verapamil<br />

Other<br />

Cough (2%)<br />

Gynecomastia (males

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!